{"id":"NCT03432533","sponsor":"Amgen","briefTitle":"A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis","officialTitle":"A Randomized, Multicenter, Open-label, Parallel Group Study in Postmenopausal Women With Osteoporosis to Evaluate the Noninferiority of Subject-administered Romosozumab Via Autoinjector/Pen vs Healthcare Provider-administered Romosozumab Via Prefilled Syringe","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-02-06","primaryCompletion":"2019-04-11","completion":"2020-01-08","firstPosted":"2018-02-14","resultsPosted":"2020-04-10","lastUpdate":"2020-11-23"},"enrollment":283,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Post-Menopausal Osteoporosis"],"interventions":[{"type":"DRUG","name":"romosozumab HCP administration with PFS","otherNames":["Evenity","AMG785"]},{"type":"DEVICE","name":"romosozumab self-administration with AI/Pen","otherNames":["Evenity","AMG785"]}],"arms":[{"label":"Romosozumab 210 mg QM: PFS","type":"ACTIVE_COMPARATOR"},{"label":"Romosozumab 210 mg QM: AI/Pen","type":"ACTIVE_COMPARATOR"}],"summary":"To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab at 90 mg/mL administered subcutaneously (SC) once a month (QM) in postmenopausal women with osteoporosis either by healthcare provider (HCP) administration with prefilled syringe (PFS) or by subject self-administration with autoinjector/pen (AI/Pen)","primaryOutcome":{"measure":"Percent Change From Baseline in Lumbar Spine BMD at Month 6","timeFrame":"Baseline, Month 6","effectByArm":[{"arm":"Romosozumab 210 mg QM: PFS","deltaMin":9.2,"sd":0.4},{"arm":"Romosozumab 210 mg QM: AI/Pen","deltaMin":9,"sd":0.5}],"pValues":[{"comp":"OG000 vs OG001","p":"0.84"}]},"eligibility":{"minAge":"55 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":7},"locations":{"siteCount":46,"countries":["United States","Poland","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":141},"commonTop":["Injection site erythema","Injection site pain","Injection site swelling","Nasopharyngitis","Arthralgia"]}}